Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.

BACKGROUND We sought to analyze the prognostic significance of the new International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) lung adenocarcinoma (ADC) classification for patients undergoing resection for small (≤2cm) lung ADC and to investigate whether histologic subtyping can predict recurrence after limited resection (LR) vs lobectomy (LO). METHODS Comprehensive histologic subtyping was performed according to the IASLC/ATS/ERS classification on all consecutive patients who underwent LR or LO for small lung ADC between 1995 and 2009 at Memorial Sloan-Kettering Cancer Center. Clinical characteristics and pathologic data were retrospectively evaluated for 734 consecutive patients (LR: 258; LO: 476). Cumulative incidence of recurrence (CIR) was calculated using competing risks analysis and compared across groups using Grey's test. All statistical tests were two-sided. RESULTS Application of IASLC/ATS/ERS lung ADC histologic subtyping to predict recurrence demonstrates that, in the LR group but not in the LO group, micropapillary (MIP) component of 5% or greater was associated with an increased risk of recurrence, compared with MIP component of less than 5% (LR: 5-year CIR = 34.2%, 95% confidence interval [CI] = 23.5% to 49.7% vs 5-year CIR = 12.4%, 95% CI = 6.9% to 22.1%, P < .001; LO: 5-year CIR = 19.1%, 95% CI = 12.0% to 30.5% vs 15-year CIR = 12.9%, 95% CI = 7.6% to 21.9%, P = .13). In the LR group, among patients with tumors with an MIP component of 5% or greater, most recurrences (63.4%) were locoregional; MIP component of 5% or greater was statistically significantly associated with increased risk of local recurrence when the surgical margin was less than 1cm (5-year CIR = 32.0%, 95% CI = 18.6% to 46.0% for MIP ≥ 5% vs 5-year CIR = 7.6%, 95% CI = 2.3% to 15.6% for MIP < 5%; P = .007) but not when surgical margin was 1cm or greater (5-year CIR = 13.0%, 95% CI = 4.1% to 22.1% for MIP ≥ 5% vs 5-year CIR = 3.4%, 95% CI = 0% to 7.7% for MIP < 5%; P = .10). CONCLUSIONS Application of the IASLC/ATS/ERS classification identifies the presence of an MIP component of 5% or greater as independently associated with the risk of recurrence in patients treated with LR.

[1]  R. Landreneau,et al.  Intraoperative brachytherapy following thoracoscopic wedge resection of stage I lung cancer. , 1998, Chest.

[2]  H. Horinouchi,et al.  Histopathological features and prognostic significance of the micropapillary pattern in lung adenocarcinoma , 2008, Modern Pathology.

[3]  Jungsil Ro,et al.  Micropapillary Component in Lung Adenocarcinoma: A Distinctive Histologic Feature With Possible Prognostic Significance , 2002, The American journal of surgical pathology.

[4]  E. Miyaoka,et al.  Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival: Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  J. Ferlay,et al.  Cancer Incidence in Five Continents , 1970, Union Internationale Contre Le Cancer / International Union against Cancer.

[6]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[7]  Jie Gu,et al.  Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients—A single institution retrospective study of 292 lung adenocarcinoma , 2012, Journal of surgical oncology.

[8]  L V Rubinstein,et al.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1995, The Annals of thoracic surgery.

[9]  Michael Thomas,et al.  The novel histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification system of lung adenocarcinoma is a stage-independent predictor of survival. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Bray,et al.  International lung cancer trends by histologic type: Male:Female differences diminishing and adenocarcinoma rates rising , 2005, International journal of cancer.

[11]  N. Isowa,et al.  Lung adenocarcinomas with micropapillary components , 2009, General thoracic and cardiovascular surgery.

[12]  E. Halm,et al.  Limited Resection for the Treatment of Patients With Stage IA Lung Cancer , 2010, Annals of surgery.

[13]  M. Hollingsworth,et al.  A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis , 2007, Modern Pathology.

[14]  Y. Ishikawa,et al.  Early-Stage Lung Adenocarcinomas With a Micropapillary Pattern, a Distinct Pathologic Marker for a Significantly Poor Prognosis , 2003, The American journal of surgical pathology.

[15]  Kenji Suzuki,et al.  A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201) , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  J. Dignam,et al.  The Use and Interpretation of Competing Risks Regression Models , 2012, Clinical Cancer Research.

[17]  V. Rusch,et al.  Visceral Pleural Invasion: Pathologic Criteria and Use of Elastic Stains: Proposal for the 7th Edition of the TNM Classification for Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  N. Tsubota,et al.  Prospective study of extended segmentectomy for small lung tumors: the final report. , 2002, The Annals of thoracic surgery.

[19]  H. Iwasaki,et al.  Micropapillary pattern: a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≤20 mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours) , 2005, Histopathology.

[20]  B. Loo,et al.  American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer. , 2012, Chest.

[21]  J. Luketich,et al.  Lobar and sublobar resection with and without brachytherapy for small stage IA non-small cell lung cancer. , 2005, The Journal of thoracic and cardiovascular surgery.

[22]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[23]  D. Heron,et al.  Dosimetric Evaluation of Radiation Exposure During I-125 Vicryl Mesh Implants: Implications for ACOSOG z4032 , 2007, Annals of Surgical Oncology.

[24]  Y. Nishiwaki,et al.  Structural and biological properties of a papillary component generating a micropapillary component in lung adenocarcinoma. , 2010, Lung cancer.

[25]  Teruaki Koike,et al.  Intentional limited pulmonary resection for peripheral T1 N0 M0 small-sized lung cancer. , 2003, The Journal of thoracic and cardiovascular surgery.

[26]  L. Tanoue.  Survival Following Lobectomy and Limited Resection for the Treatment of Stage I Non-small Cell Lung Cancer ≤1cm in Size: A Review of SEER Data , 2012 .

[27]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[28]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  V. Rusch,et al.  Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. , 2011, Journal of Clinical Oncology.

[30]  蒔本 好史.  Micropapillary pattern : a distinct pathological marker to subclassify tumours with a significantly poor prognosis within small peripheral lung adenocarcinoma (≦20mm) with mixed bronchioloalveolar and invasive subtypes (Noguchi's type C tumours) , 2005 .

[31]  J. Miller,et al.  Limited resection of bronchogenic carcinoma in the patient with marked impairment of pulmonary function. , 1987, The Annals of thoracic surgery.

[32]  R. Landreneau,et al.  Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non-small-cell lung cancer. , 2003, Surgery.

[33]  Masahiro Tsuboi,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[34]  C. Sima,et al.  FDG-PET SUVmax Combined with IASLC/ATS/ERS Histologic Classification Improves the Prognostic Stratification of Patients with Stage I Lung Adenocarcinoma , 2012, Annals of Surgical Oncology.

[35]  M. Okada,et al.  Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. , 2005, The Journal of thoracic and cardiovascular surgery.

[36]  R. Landreneau,et al.  Segmental resection spares pulmonary function in patients with stage I lung cancer. , 2004, The Annals of thoracic surgery.

[37]  R. Keenan,et al.  Mature follow-up for high-risk stage I non-small-cell lung carcinoma treated with sublobar resection and intraoperative iodine-125 brachytherapy. , 2011, International journal of radiation oncology, biology, physics.

[38]  Akihiko Yoshizawa,et al.  Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases , 2011, Modern Pathology.

[39]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[40]  S. Swanson,et al.  Survival following lobectomy and limited resection for the treatment of stage I non-small cell lung cancer<=1 cm in size: a review of SEER data. , 2011, Chest.